Top

Published in:

Open Access 01-12-2016 | Review

Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How

Authors: Olubanke Davies, Andrew Ustianowski, Julie Fox

Published in: Infectious Diseases and Therapy | Issue 4/2016

Abstract

Pre-exposure prophylaxis (PrEP) offers a promising new approach to HIV prevention. It is protective against HIV infection across populations and has few significant safety risks and little evidence of behavioural risk compensation. This article summarises the evidence behind HIV PrEP as an intervention, populations that may benefit, current guidelines and programmes, and the cost-effectiveness modelling of this strategy.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed

McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRefPubMedPubMedCentral

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed

Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–46.CrossRefPubMed

Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef

Rees H, Delany-Moretlwe S, Baron D, Lombard C, Gray G, Myer L, et al., editors. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. Conference on Retroviruses and Opportunistic Infections (CROI); 2015.

Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.CrossRefPubMedPubMedCentral

10.

Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.CrossRefPubMedPubMedCentral

11.

Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed

12.

Kasonde M, Niska RW, Rose C. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One. 2014;9(3):e90111.CrossRefPubMedPubMedCentral

13.

Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial: DXA results from iPrEx. Clin Infect Dis. 2015;61(4):572–80.CrossRefPubMedPubMedCentral

14.

Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851–9.CrossRefPubMedPubMedCentral

15.

Massud I, Mitchell J, Babusis D, Garcia-Lerma G, et al. Chemoprophylaxis with Oral FTC/TAF protects macaques from rectal SHIV infection. Conference on retroviruses and opportunistic infections. Boston, February 22–25, 2016. Abstract 107.

16.

Garrett KL, Cottrell ML, Prince HMA. Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF. Conference on retroviruses and opportunistic infections (CROI). February 22–25, 2016, Boston.

17.

Ford N, et al. Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One. 2013;8(11):e79981. doi:10.1371/journal.pone.0079981.CrossRefPubMedPubMedCentral

18.

Fox J, Herrera C, Tiraboschi JM et al. Pharmacokinetic/pharmacodynamic investigation of single dose oral maraviroc in the context of HIV-1 pre exposure prophylaxis. JAIDS. 2016 (Epub ahead of print).

19.

McGowan I for the HPTN 069/ACTG 5305 Team PrEP impact on T-cell activation and explant infection: HPTN 069/ACTG 5305 study. Conference on Retroviruses and Opportunistic Infections (CROI 2016), Boston. Oral presentation#104. 2016.

20.

Gulick R, et al. HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in United States (U.S.) women. AIDS 2016, Durban. Oral abstract TUAC0102.

21.

Gulick R, Wilkin TJ, Chen Y, et al. HPTN 069/ACTG 5305: phase II study of maraviroc-based regimens for HIV PrEP in MSM. Conference on retroviruses and opportunistic infections (CROI), February 22–25, 2016, Boston. Abstract 103. http://www.how2offerprep.org/.

22.

Markowitz M et al. ÉCLAIR: phase 2a safety and PK study of cabotegravir LA in HIV-infected men. Conference on retroviruses and opportunistic infections, Boston, 2016. Abstract 106.

23.

Baeten JM, Palanee-Phillips T, Brown ER et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. Published online February 22, 2016. doi:10.1056/NEJMoa1506110.

24.

Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012;14:17–27.PubMed

25.

Grant R. Complications from head to toe. Presentation at conference on retroviruses and opportunistic infections, Feb 22–25, 2016. Seattle.

26.

World Health Organization. WHO HIV Drug resistance report 2012. Available from: http://www.who.int/hiv/pub/drugresistance/report2012/en/. Accessed 26 Jun 2016.

27.

Gupta RK, Wainberg MA, Brun-Vezinet F, et al. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. J Infect Dis. 2013;207(Suppl 2):S101–6.CrossRefPubMedPubMedCentral

28.

Hamers RL, Oyomopito R, Kityo C, et al. The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance–HIV drug resistance in sub-Saharan Africa and the Asia-Pacific 21 April 2011. Int J Epidemiol. 2012;41(1):43–54.CrossRefPubMed

29.

Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11:750–9.CrossRefPubMed

30.

Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.CrossRefPubMedPubMedCentral

31.

US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed 26 Jun 2016.

32.

Mera RM, Rawlings MK, Pechonkina A, Rooney JF, Peschel T, Cheng A. Status of Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) in the United States: an early drug utilization analysis. Paper presented at: 53rd ICAAC interscience conference on antimicrobial agents and chemotherapy, September 10–13, 2013, Denver.

33.

European AIDS Clinical Society guidelines. 2015; Version 8: Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed 26 Jun 2016.

34.

World Health Organisation. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015. Available from: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/. Accessed 26 June 2016.

35.

European Centre for Disease Control. HIV and STI prevention among men who have sex with men. http://ecdc.europa.eu/en/publications/publications/hiv-sti-prevention-among-men-who-have-sex-with-men-guidance.pdf. Accessed 26 June 2016.

36.

European Medicines Agency. First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002578.jsp&mid=WC0b01ac058004d5c1. Accessed 16 Aug 2016.

37.

Centers for disease control and prevention. US Public Health Service Preexposure prophylaxis for the prevention of HIV infection in the United States-2014. A clinical practice guideline. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed 26 Jun 2016.

38.

Australia’s Therapeutic Goods Administration. Prescription medicines: new or extended uses, or new combinations of registered medicines. https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines. Accessed 26 Jun 2016.

39.

Cambiano VMA, Dunn D, McCormack S, Ong K, Gill N, Nardone A, Desai M, Rodger A, Phillips A. Is pre-exposure prophylaxis for HIV prevention cost-effective in men who have sex with men in the UK? BASHH Spring Conference; Glasgow 2015.

40.

Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: a systematic review and meta-analysis. AIDS. 2016;30(12):1973–83.CrossRefPubMedPubMedCentral

41.

Ross EL, Cinti SK, Hutton DW. Implementation and operational research: a cost-effective, clinically actionable strategy for targeting HIV pre-exposure prophylaxis to high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2016;72(3):e61–7.CrossRefPubMed

42.

Ying R, Heffron R, Celum C, Baeten JM, Katabira E, Bulya N, et al. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J Int AIDS Soc. 2015;18:20013.CrossRefPubMedPubMedCentral

43.

Cambiano V, Miners A, Phillips A. What do we know about the cost–effectiveness of HIV preexposure prophylaxis, and is it affordable? Curr Opin HIV AIDS. 2016;11(1):56–66.CrossRefPubMed

44.

Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of PrEP in the United States in MSM. Ann Intern Med. 2012;156(8):541–50.CrossRefPubMedPubMedCentral

45.

Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral

46.

Cambiano V. Cost-effectiveness of ART as prevention Unpublished conference presentation at British HIV Association annual conference, April 20, 2016. Manchester.

47.

Bernard CL, Brandeau ML, Humphreys K, et al. Cost-effectiveness of HIV preexposure prophylaxis for people who inject drugs in the United States. Ann Intern Med. 2016. doi:10.7326/M15-2634 (Epub ahead of print).

48.

Mitchell KM, Lépine A, Terris-Prestholt F, et al. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. AIDS. 2015;29(15):2035–44.CrossRefPubMedPubMedCentral

49.

Nichols BE, Baltussen R, van Dijk JH, et al. Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. J Acquir Immune Defic Syndr. 2014;66:221–8.PubMed

50.

UNAIDS 90-90-90. An ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed 16 Aug 2016.

51.

Schneider K, Gray RT. Wilson DP a cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia. Clin Infect Dis. 2014;58(7):1027–34. doi:10.1093/cid/cit946.CrossRefPubMed

Title: Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
Authors: Olubanke Davies
Andrew Ustianowski
Julie Fox
Publication date: 01-12-2016
Publisher: Springer Healthcare
Published in: Infectious Diseases and Therapy / Issue 4/2016
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-016-0128-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis

Cross-Sectional Survey of Perceived Barriers Among Community Pharmacists Who Do Not Immunize, in Wayne County, Michigan

A Retrospective Study of the Impact of Rapid Diagnostic Testing on Time to Pathogen Identification and Antibiotic Use for Children with Positive Blood Cultures

The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page